RPRX vs. TMO: Royalty Pharma vs. Thermo Fisher Scientific Stock Comparison

Company Profile

Royalty Pharma (RPRX) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RPRX is classified in Pharmaceuticals while TMO is classified in Life Sciences Tools & Services.

Thermo Fisher Scientific (TMO) has more than two decades of public-market history since March 17, 1980, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Royalty Pharma (RPRX) at 12.09% and Thermo Fisher Scientific (TMO) at 13.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Royalty Pharma (RPRX) at 25.70% keeps the most of each sales dollar — above its industry’s net margin range — and Thermo Fisher Scientific (TMO) at 14.94% also retains a top-quartile share.

Both Royalty Pharma (RPRX) at 81.32% and Thermo Fisher Scientific (TMO) at 20.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Royalty Pharma (RPRX) at 5.06% and Thermo Fisher Scientific (TMO) at 3.91% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Royalty Pharma (RPRX) at 23.09% and Thermo Fisher Scientific (TMO) at 7.32% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Royalty Pharma (RPRX) at 1.29 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Royalty Pharma (RPRX) at 0.88 and Thermo Fisher Scientific (TMO) at 0.75 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Both Royalty Pharma (RPRX) at 1.37% and Thermo Fisher Scientific (TMO) at 0.27% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Royalty Pharma (RPRX) at 60.46% and Thermo Fisher Scientific (TMO) at 9.70% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Thermo Fisher Scientific (TMO) at 36.64 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Royalty Pharma (RPRX) at 14.79 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Royalty Pharma (RPRX) at 4.39 and Thermo Fisher Scientific (TMO) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics